Abstract
Infectious complications in chronic lymphocytic leukemia (CLL) represent a major cause of morbidity and mortality. The aim of the study was to investigate temporal trends in bloodstream infections (BSIs) among patients with CLL. Individuals with blood cultures were linked to Swedish Cancer Registry and divided into three time periods (1988–1993, 1994–1999, and 2000–2006) according to year of CLL diagnosis. CLL patients (n = 275) with 1092 blood culture episodes were identified and linked to the nationwide Cause of Death Registry and Swedish Patient Registry (to retrieve information on splenectomies). The most common causes of BSI among CLL patients were Escherichia coli (11/43, 15/78, and 9/33), Streptococcus pneumoniae (7/43, 13/78, and 6/33), Pseudomonas aeruginosa (2/43, 8/78, and 3/33), Staphylococcus aureus (1/43, 6/78, and 6/33), and Viridans streptococci (5/43, 6/78, and 2/33). Coagulase-negative staphylococci was the most frequent microorganism found in blood cultures (22/70, 23/106, and 5/41, respectively) but is a frequent contaminant. Based on the largest study to date on BSI in CLL patients, we found a stable proportion of Gram-positive to Gram-negative bacteria and no temporal change of distribution was observed for BSIs 1988–2006.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in the Western world with an incidence of approximately 5 per 100,000 person-years in Sweden [1]. It affects men approximately twice as frequently as women and is a disease of older people with a median age at diagnosis of approximately 71 years. Clinical management of CLL patients has improved considerably over recent years, to which an increased use of prognostic markers, introduction of new therapeutic agents and procedures, and improved supportive care measures all have contributed [2, 3].
Infectious complications have since long been recognized as a major cause for morbidity and mortality in patients with CLL [4, 5]. Based on studies from 1970s to 1990s, the overall mortality from infections ranges from 30 to 50 %; however, large studies on CLL patients diagnosed in more recent years are lacking [6]. The pathogenesis of infections in CLL patients is multifactorial and is related to inherent immune defects and therapy-related immunosuppression [7]. The inherent immune dysfunction is characterized by defects in both humoral and cell-mediated immunity. Cytotoxic chemotherapy also targets normal immune cells, thus exacerbating this immunosuppression. Splenectomy or hyposplenism (secondary to irradiation to spleen) performed for complications of CLL including autoimmune hemolytic anemia or thrombocytopenia, hypersplenism, and symptomatic splenomegaly is associated with complex innate and adaptive immune responses [8]. Overwhelming post-splenectomy infection is a rare medical emergency [9, 10]. Use of alemtuzumab is associated with neutropenia and reductions in B, T, and NK cells and rituximab with transient reduction of B cell counts; both antibodies are associated with increased risk of infections [11].
Apart from data based on clinical trials and smaller case studies, there is a lack of detailed knowledge on bloodstream infections (BSIs) in CLL patients, their impact on survival, and the effect of the anti-tumoral treatments on the distribution of causative pathogens over time. We thus performed a study, based on blood cultures sampled from CLL patients which were analyzed 1988–2006 at the Clinical Microbiology Laboratory, Karolinska University Hospital Solna, Sweden. The aims were to identify all culture-verified blood cultures, to identify potential changes of causative agents over time, and to record changes in patient survival.
Patient and methods
Data sources and study population
In Sweden, more than 96 % of all new cancers are reported to the national Swedish Cancer Registry, which was established in 1958 and has a high coverage for hematological malignancies [1, 12, 13]. Every physician and pathologist/cytologist is obliged by law to report each occurrence of cancer to the registry.
All blood cultures that were analyzed at the Karolinska University Hospital’s Clinical Microbiology Laboratory were identified, and individuals who had at least one blood culture analyzed between 1988 and 2006 were registered (Fig. 1). Individuals with a drawn blood culture were linked to the nationwide Swedish Cancer Registry to identify all persons diagnosed with CLL. Only CLL patients with a blood culture drawn at the same date or after CLL diagnosis were included in the analyses. A positive blood culture included growth of any microorganism in blood culture. A BSI was defined as growth of bacteria in blood culture excluding commonly found contaminants [14]. Growth of the same microorganism within 7 days was considered as the same BSI episode.
Information from the nationwide Cause of Death Registry (with data from 1954) was used to retrieve dates of death, and the Swedish Patient Registry (with data from 1964) was used to retrieve information on individual patient-based discharge diagnoses from inpatient and outpatient care [15].
Approval for this study was obtained from the Regional Ethical Review Board in Stockholm (record 2007/1307-31/5).
Statistical methods
Patient characteristics as well as bacterial findings were analyzed for three separate time periods of CLL diagnosis (1988–1993, 1994–1999, and 2000–2006; June 30). To evaluate survival after diagnosis of CLL, by blood culture pattern, data was analyzed using survival analysis methods with the event of interest being all-cause mortality during follow-up. Risk time was accumulated from date of first blood culture following diagnosis until death or December 31, 2009, whichever occurred first. Time since CLL diagnosis was used as the underlying timescale in all analyses. Crude mortality rates (and 95 % confidence intervals [CIs]) were calculated as number of events per 1000 person-years. The exposure of interest was a BSI following CLL diagnosis and was analyzed both as a dichotomous variable (“ever” vs “never”) and as time-varying (“after” vs “before” or “never”). The effect of having had a splenectomy on survival was evaluated in a separate model. To evaluate possible associations, Cox proportional hazard models were used, yielding hazard ratios (HRs) with 95 % CIs. The proportional hazard assumption was formally assessed in all models, and no evidence suggested that this assumption was violated. Analyses were adjusted for time since diagnosis, sex, and age at diagnosis. The effect of the exposure was estimated separately for the three time periods of diagnosis by including an interaction term in the models. As a sensitivity analysis, to obtain similar time to first culture between different calendar periods, the cohort was restricted to patients diagnosed before June 30, 2005 who had their first culture within 1 year following diagnosis. Difference in proportion of BSI between time periods was tested using a chi-squared test or Fisher’s exact test. Difference in mean time to culture was tested using a t test.
Stata v.12 software was used for the statistical analyses (StataCorp, College Station, TX, USA).
Results
A total of 275 CLL patients, diagnosed between January 1, 1988 and June 30, 2006, were included in the study. Among these CLL patients, a total of 1092 blood culture episodes were identified. The mean time between CLL diagnosis and first drawn blood culture was significantly shorter in the most recent time period (6.2, 4.7, and 2.4 years for the time periods 1988–1993, 1994–1999, and 2000–2006, respectively (p value <0.001); Table 1).
In the last time period, patients had a significant lower percentage of positive blood cultures (51.5, 45.9, and 28.2 %, respectively (p value 0.007)). Similarly, the percentage of patients with at least one BSI decreased significantly (38.2, 38.5, and 22.4 %, respectively (p value 0.033)). In a sensitivity analysis including only patients diagnosed until 2005 with their positive blood culture within a year of diagnosis, the decline remained statistically significant both for BSI (71.4, 36.4, and 13.8 %; p value 0.008) and for all positive blood cultures (71.4, 50.0, and 24.1 %; p value 0.033; Fig. 2).
Positive blood cultures were observed in 115 CLL patients, with 215 positive blood cultures for bacteria and two episodes of candidemia. Dominating bacterial species were coagulase-negative staphylococci (CoNS) (22 (31 %), 23 (22 %), and 5 (12 %), for the three time periods, Escherichia coli (11 (16 %), 15 (14 %), and 9 (22 %)), Streptococcus pneumoniae (7 (10 %), 13 (12 %), and 6 (15 %)), Pseudomonas aeruginosa (2 (3 %), 8 (8 %), and 3 (7 %)), Staphylococcus aureus (1 (1 %), 6 (6 %), and 6 (15 %)), and Viridans streptococci (5 (7 %), 6 (6 %), and 2 (5 %)); Table 2). Excluding common contaminants (CoNS, Micrococcus spp., Corynbacterium spp., Bacillus spp., Proprionbacterium acnes, and Gram-positive bacillus (not further specified), 152 bacterial BSI (hereafter BSI) episodes (42, 77, and 33 in respective time period) and two episodes of candidemia were found. Excluding strictly anaerobes and fungi, the percentage of Gram-positive vs Gram-negative bacteria remained stable in the three time periods, respectively (61.4 vs 31.4 %, 54.7 % vs 34.0 %, and 65.9 vs 31.7 %; Table 2).
Mortality rates and relative risks of death among CLL patients with at least one positive blood culture or BSI at or following diagnosis, compared to patients with only negative blood culture episodes, or negative blood culture episodes including cultures with finding of contaminants, are presented in Table 3. In the last time period, mortality among patients with a BSI was significantly higher compared to patients with either a contaminant or a negative blood culture (HR = 2.52, 95 % CI 1.44–4.41), as well as compared to patients with negative blood cultures alone (HR = 2.44, 95 % CI 1.38–4.30), when adjusting for time since diagnosis, age at diagnosis, and sex. Being splenectomized did not significantly affect mortality during any of the three time periods (HR = 0.97, 95 % CI 0.38–2.48; HR = 0.45, 95 % CI 0.19–1.06; and HR = 0.64, 95 % CI 0.25–1.60; Table 3).
In a sensitivity analysis, including only patients diagnosed until 2005 with their first culture within a year of diagnosis, the mortality rate was higher during 1994–1999 among patients with a BSI, as compared to patients with a contaminant or a negative blood culture (HR = 2.94, 95 % CI 1.04–8.33), as well as compared to patients with a negative blood culture alone (HR = 5.72, 95 % CI 1.74–18.7). During the same time period, the mortality rate was also higher comparing all positive blood cultures to negative blood cultures (HR = 3.55, 95 % CI 1.34–9.44; Table 3, lower panel).
When analyzing positive blood culture as a time-varying exposure, mortality was significantly higher among patients with a BSI both during 1994–1999 (HR = 2.59, 95 % CI 1.74–3.85) and 2000–2006 (HR = 3.21, 95 % CI 1.83–5.62; Table 4). In a sensitivity analysis, the mortality among patients with BSI was significantly higher (HR = 5.07, 95 % CI 1.33–19.3) in the middle time period (data not shown).
Discussion
In this large study based on 1092 blood culture episodes from 275 CLL patients analyzed between 1998 and 2006 at Karolinska University Hospital Solna, we found a stable proportion of Gram-positive to Gram-negative bacteria and no changes in distribution of bacterial species were observed, with the dominating BSI pathogens being E. coli, S. pneumoniae, P. aeruginosa, S. aureus, and V. streptococci. CoNS was the most frequently detected microorganism in blood cultures but is a frequent contaminant. Our study is of importance given concerns of infectious complications using new treatment options and highlights real-life data in a large cohort of CLL patients.
We found a significant decrease in proportion of positive blood cultures and BSI between 1994 and 1999 and between 2000 and 2006. This is in contrast to earlier experiences from blood cultures collected from the hematology ward 1988–2008 in the same institution, where we observed stable percentage of positive blood cultures over time [16]. A possible explanation could be the introduction of combination treatments including monoclonal antibodies [17–19]. We speculate that more effective therapy given in recent years, which leads to deeper responses and longer time to next progression, results in the observed reduction of positive blood cultures and BSI. Our results are supported by a study from the UK where a trend to lower rates of BSI over three 12-month periods was observed [20]. On the other hand, in more aggressive hematological diseases, BSI seems to have increased in another UK center between 2004 and 2010 [21]. However, anti-bacterial prophylaxis, non-comparable use of anti-cancer therapy, and different overall survival make comparisons difficult. Moreover, stated limitations preclude us from interpreting any trends from our data in proportion of positive blood cultures or BSI.
The stable distribution between Gram-positive and Gram-negative bacteria observed in this study is similar to an observation by Francis et al. [22]. Nevertheless, in two reviews of BSI in hematology and cancer patients and a questionnaire on the etiology of BSI in conjunction with the Fourth European Conference on Infections in Leukemia (2011), a recent trend in increased number of infections caused by Gram-negative bacilli was found [23, 24]. The proposed explanation is decreased use and shorter duration of anti-bacterial prophylaxis and, to a lesser extent, decreased use of indwelling catheters and cytotoxic chemotherapy. Trimethoprim/sulfamethoxazole effectively reduces risk of Pneumocystis jirovecii pneumonia and also reduces the incidence of BSI [25–27]. Considering the scarce use of fluoroquinolone prophylaxis and indwelling catheters in CLL, comparisons of trends in BSI with other malignancies must be done with caution.
During the study period, the anti-tumoral armamentarium has expanded and treatment has remained reserved for patients with systemic symptoms or progressive disease [28]. The monoclonal anti-CD-20 antibody rituximab in combination with FC was shown in 2005 to further improve response rates [18, 19]. For rituximab and other anti-tumoral agents, only scarce information on BSI in CLL exists [6, 11, 18, 19, 29–32]. Furthermore, major infectious complications increase with previously received anti-tumoral therapies [33, 34]. Our results on the most common pathogens in BSI might affect anti-biotic choice when empirical therapy in CLL patients with signs and symptoms of BSI is considered.
We found BSI to be associated with worse prognosis especially during the latter time periods, but limitations of our study may bias our results. The effect was seen both when treating blood cultures as a dichotomous exposure and as time-varying. This has to our knowledge not been shown previously in CLL patients. To evaluate this further, we did sensitivity analysis on a homogenous group of more high-risk patients, by only including patients diagnosed 1988 to 2005 who had a culture within 1 year of diagnosis. The point estimates during 1999–2005 remained of similar magnitude, although slightly smaller as compared to those from the full cohort analysis, and they were no longer statistically significant. However, fewer deaths in this analysis made power to detect potential differences small, which is reflected in the wide confidence intervals. During the middle period, where event counts were larger, a significantly higher mortality was observed among patients with BSI. This, together with the non-significant risk increase in the last time period, support the hypothesis that among more high-risk patients, a positive blood culture results in higher mortality. In a retrospective study of BSI 1988–2008, from the same institution, anti-biotic resistance was stable and should therefore not influence our results on temporal trends in mortality rate [16]. We speculate if CLL patients in later time periods, due to introduction of immunotherapy, had developed therapy-related immunodeficiencies in their adaptive immune response, with less favorable outcomes of BSI. Our study includes a stable number of splenectomies among CLL patients during the study period. No statistically significant differences in mortality were seen when comparing patients with splenectomy to those without. However, the numbers of splenectomies were small, and thus, the results are limited by power.
To our knowledge, this is the first study to examine the risk for and distribution of BSI in patients with CLL. Previous reports have presented BSI in all hematological diseases as a group [16, 35], presented mortality rates for CLL with BSIs or major infections without displaying CLL-specific pathogen distribution [36, 37], or only presented very few BSIs among CLL patients [17]. The main strengths are the large sample size from a single institution, the use of high-quality registries, and the uniform treatment according to national guidelines. Our study has some important limitations. Generalizability is impeded by the retrospective data and that data consists of CLL patients with drawn blood culture, rather than all CLL patients. Information on important clinical descriptors were not available as, for example, anti-tumoral treatment, anti-microbial prophylaxis, anti-microbial resistance, and site of drawn blood culture. For clinical purpose, we therefore excluded pathogens known to be possible contaminants even though delineation of clinical significance can be difficult in the immunocompromised host. For the latter time period, due to administrative censoring, time window for having a blood culture drawn was shorter as compared to that for patients diagnosed during the earlier time periods. Low counts of exposure and events further hampered our possibilities to draw strong conclusions on temporal differences in the sensitivity analyses of BSI and mortality. Lastly, the design of the study, organizing 1.8 million microbial analyzes and then cross-matching data against three national registries, rendered delays in presentation of results.
In summary, based on the largest study to date on BSI in CLL patients, we found a stable proportion of Gram-positive to Gram-negative bacteria for BSIs 1988–2006. The most common pathogens of BSI were E. coli, S. pneumoniae, P. aeruginosa, S. aureus, and V. streptococci, and no temporal change of distribution was observed. Surveying treatment-related infections and optimizing prophylaxis will be important objectives when improving anti-tumoral treatments for CLL.
References
Regionalt cancercentrum Stockholm-Gotland [Internet] (2013) Kronisk Lymfatisk Leukemi, Nationella riktlinjer för utredning och behandling. http://www.cancercentrum.se/sv/stockholmgotland/VP_register/blodcancer/KLL/vardprogram-register/. Accessed June 2015
Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Bjorkholm M, Landgren O (2009) Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973–2003 in Sweden. Haematologica 94(9):1259–1265. doi:10.3324/haematol.2009.007849
Desai AV, El-Bakkar H, Abdul-Hay M (2014) Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future. Clin Lymphoma, Myeloma Leuk. doi:10.1016/j.clml.2014.09.007
Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M (1987) Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood 69(3):929–936
Twomey JJ (1973) Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med 132(4):562–565
Molica S (1994) Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leuk Lymphoma 13(3–4):203–214. doi:10.3109/10428199409056283
Wadhwa PD, Morrison VA (2006) Infectious complications of chronic lymphocytic leukemia. Semin Oncol 33(2):240–249. doi:10.1053/j.seminoncol.2005.12.013
Cusack JC Jr, Seymour JF, Lerner S, Keating MJ, Pollock RE (1997) Role of splenectomy in chronic lymphocytic leukemia. J Am Coll Surg 185(3):237–243
Serio B, Pezzullo L, Giudice V, Fontana R, Annunziata S, Ferrara I, Rosamilio R, De Luca C, Rocco M, Montuori N, Selleri C (2013) OPSI threat in hematological patients. Transl Med UniSa 6:2–10
Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O (2014) Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica 99(2):392–398. doi:10.3324/haematol.2013.092460
Morrison VA (2014) Infections in patients with leukemia and lymphoma. Cancer Treat Res 161:319–349. doi:10.1007/978-3-319-04220-6_11
Barlow L, Westergren K, Holmberg L, Talback M (2009) The completeness of the Swedish cancer register: a sample survey for year 1998. Acta Oncol 48(1):27–33. doi:10.1080/02841860802247664
Turesson I, Linet MS, Bjorkholm M, Kristinsson SY, Goldin LR, Caporaso NE, Landgren O (2007) Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964–2003. Int J Cancer 121(10):2260–2266. doi:10.1002/ijc.22912
Pien BC, Sundaram P, Raoof N, Costa SF, Mirrett S, Woods CW, Reller LB, Weinstein MP (2010) The clinical and prognostic importance of positive blood cultures in adults. Am J Med 123(9):819–828. doi:10.1016/j.amjmed.2010.03.021
Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11:450. doi:10.1186/1471-2458-11-450
Kjellander C, Bjorkholm M, Cherif H, Kalin M, Giske CG (2012) Hematological: low all-cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: a single-center study. Eur J Haematol 88(5):422–430. doi:10.1111/j.1600-0609.2012.01768.x
Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, Mayer J (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol: Off J Am Soc Clin Oncol 25(35):5616–5623. doi:10.1200/JCO.2007.12.9098
Keating MJ, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol: Off J Am Soc Clin Oncol 23(18):4079–4088. doi:10.1200/JCO.2005.12.051
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S, International Group of I, German Chronic Lymphocytic Leukaemia Study G (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164–1174. doi:10.1016/S0140-6736(10)61381-5
Jugo J, Kennedy R, Crowe MJ, Lamrock G, McClurg RB, Rooney PJ, Morris TC, Johnston PG (2002) Trends in bacteraemia on the haematology and oncology units of a UK tertiary referral hospital. J Hosp Infect 50(1):48–55. doi:10.1053/jhin.2001.1101
Huoi C, Vanhems P, Nicolle MC, Michallet M, Benet T (2013) Incidence of hospital-acquired pneumonia, bacteraemia and urinary tract infections in patients with haematological malignancies, 2004–2010: a surveillance-based study. PLoS One 8(3), e58121. doi:10.1371/journal.pone.0058121
Francis S, Karanth M, Pratt G, Starczynski J, Hooper L, Fegan C, Pepper C, Valcarcel D, Milligan DW, Delgado J (2006) The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer 107(5):1023–1033. doi:10.1002/cncr.22094
Montassier E, Batard E, Gastinne T, Potel G, de La Cochetiere MF (2013) Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis: Off Publ Eur Soc Clin Microbiol 32(7):841–850. doi:10.1007/s10096-013-1819-7
Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, Akova M, Fourth European Conference on Infections in Leukemia Group ajvoEEIELN, Esgich/Escmid (2014) Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect 68(4):321–331. doi:10.1016/j.jinf.2013.12.006
Gurwith MJ, Brunton JL, Lank BA, Harding GK, Ronald AR (1979) A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med 66(2):248–256
Wininger DA, Fass RJ (2002) Impact of trimethoprim-sulfamethoxazole prophylaxis on etiology and susceptibilities of pathogens causing human immunodeficiency virus-associated bacteremia. Antimicrob Agents Chemother 46(2):594–597
Kalin M, Kristinsson SY, Cherif H, Lebbad M, Bjorkholm M (2010) Fatal pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma patients. Ann Hematol 89(5):523–525. doi:10.1007/s00277-009-0833-4
Boyd K, Dearden CE (2008) Alemtuzumab in the treatment of chronic lymphocytic lymphoma. Expert Rev Anticancer Ther 8(4):525–533. doi:10.1586/14737140.8.4.525
Anaissie EJ, Kontoyiannis DP, O’Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129(7):559–566
Hequet O, de Jaureguiberry JP, Jaubert D, Gisserot O, Muzellec Y, Brisou P (1997) Listeriosis after fludarabine treatment for chronic lymphocytic leukemia. Hematol cell Ther 39(2):89–91
Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA, Minnie Pearl Cancer Research N (2003) Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol: Off J Am Soc Clin Oncol 21(9):1746–1751. doi:10.1200/JCO.2003.09.027
Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR (2006) Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis: Off Publ Inf Dis Soc Am 43(1):16–24. doi:10.1086/504811
Tam CS, O’Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112(4):975–980. doi:10.1182/blood-2008-02-140582
Wierda W, O’Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol: Off J Am Soc Clin Oncol 23(18):4070–4078. doi:10.1200/JCO.2005.12.516
Bruun B, Bangsborg J, Hovgaard D, Skinhoj P (1988) Bacteremia and candidemia in hematological malignancies: microbiological findings and antibiotic susceptibilities. Scand J Infect Dis 20(5):503–509
Norgaard M, Larsson H, Pedersen G, Schonheyder HC, Sorensen HT (2006) Risk of bacteraemia and mortality in patients with haematological malignancies. Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis 12(3):217–223. doi:10.1111/j.1469-0691.2005.01298.x
Visentin A, Compagno N, Cinetto F, Imbergamo S, Zambello R, Piazza F, Semenzato G, Trentin L, Agostini C (2015) Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica. doi:10.3324/haematol.2015.126763
Acknowledgments
We would like to thank Blodcancerfonden, the Swedish Cancer Society, the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, the Karolinska Institutet Foundations, Adolf H. Lundin Charitable Foundation, Cathrine Everts Research Foundation, the University of Iceland Research Fund, Icelandic Centre for Research (RANNIS), and Landspitali University Hospital Research Fund.
Contribution
C Kjellander, SY Kristinsson, O Källman, and M Björkholm designed the study. C Kjellander and SY Kristinsson drafted the manuscript. O Källman, TJ Löve, O Landgren, and SY Kristinsson set up the database. CE Weibull and C Kjellander performed the statistical analyses. All authors contributed to the writing of the final manuscript. All the authors were involved in the interpretation of the results; read, gave comments, and approved the final version of the manuscript; had full access to the data in the study; and take responsibility for the accuracy of the data analysis.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethic approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.
Rights and permissions
About this article
Cite this article
Kjellander, C., Björkholm, M., Källman, O. et al. Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study. Ann Hematol 95, 871–879 (2016). https://doi.org/10.1007/s00277-016-2643-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-016-2643-9